For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,361 | 2,593 | ||
| General and administrative | 2,687 | 3,071 | ||
| Total operating expense | 5,048 | 5,664 | ||
| Loss from operations | -5,048 | -5,664 | ||
| Interest expense-Nonrelated Party | 31 | 29 | ||
| Interest expense-Related Party | 10 | 23 | ||
| Grant income | - | 0 | ||
| Change in fair value of other liabilities and derivatives-Nonrelated Party | 93 | 18 | ||
| Change in fair value of other liabilities and derivatives-Related Party | 7 | 1 | ||
| Other income (expense), net | 18 | -22 | ||
| Total other income (expenses), net | -123 | -93 | ||
| Loss before income taxes | -5,171 | -5,757 | ||
| Income tax provision | 10 | 4 | ||
| Net loss | -5,181 | -5,761 | ||
| Net loss attributable to noncontrolling interest | -32 | -46 | ||
| Net loss attributable to controlling interest | -5,149 | -5,715 | ||
| Deemed dividend on warrants | -5,673 | 0 | ||
| Net loss attributable to common stockholders | -10,822 | -5,715 | ||
| Basic EPS | -2.21 | -1.99 | ||
| Diluted EPS | -2.21 | -1.99 | ||
| Basic Average Shares | 4,907 | 2,877 | ||
| Diluted Average Shares | 4,907 | 2,877 | ||
Calidi Biotherapeutics, Inc. (CLDWW)
Calidi Biotherapeutics, Inc. (CLDWW)